sipuleilla

Sipuleucel-T (also known as sipuleucel-T) is a cancer immunotherapy drug used to treat patients with high-risk prostate cancer that has spread to the bones. It is a cellular immunotherapy that uses a patient's own immune cells to fight cancer. The drug is derived from the patient's own peripheral blood stem cells, which are processed to create a product called sipuleucel-T. This product is then infused back into the patient to stimulate their immune system to attack cancer cells.

The active ingredient in sipuleucel-T is a type of immune cell called a dendritic cell. These cells are modified in the laboratory to express a protein called prostatic acid phosphatase (PAP), which is found on the surface of prostate cancer cells. This modification allows the dendritic cells to recognize and attack prostate cancer cells more effectively.

Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) in 2010 and by the European Medicines Agency (EMA) in 2011. It is administered through an intravenous infusion and is typically given every two weeks for a total of four infusions.

The most common side effects of sipuleucel-T include flu-like symptoms, such as fever, chills, and fatigue. More serious side effects can include infections, low blood cell counts, and allergic reactions. It is important for patients to discuss any side effects or concerns with their healthcare provider.

Clinical trials have shown that sipuleucel-T can improve overall survival and quality of life for patients with high-risk prostate cancer that has spread to the bones. However, it is not a cure for the disease and should be used in conjunction with other treatments, such as hormone therapy and radiation.